RP7214

DRUG2 trials

Sponsors

Rhizen Pharmaceuticals SA

Conditions

Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaHealthy VolunteersMyelodysplastic Syndromes

Phase 1

A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects

CompletedNCT04680429

Rhizen Pharmaceuticals SAHealthy Volunteers

Start: 2020-12-29End: 2021-07-19Updated: 2021-08-18

Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

WithdrawnNCT05246384

Rhizen Pharmaceuticals SAAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes

Start: 2023-01-31End: 2025-11-30Updated: 2022-10-31

Related Papers

A first in man study to evaluate the safety, pharmacokinetics and pharmacodynamics of RP7214, a dihydroorotate dehydrogenase inhibitor in healthy subjects

British Journal of Clinical Pharmacology2022-10-115 citations